MTOR and urinary bladder carcinoma: Notably, treatment with mTOR inhibitors has been observed to enhance the therapeutic efficacy of cisplatin and gemcitabine in bladder cancer cell lines (32,42,43), and impair tumour progression when administered intravesically in a bladder cancer mouse model (44).